| Literature DB >> 30791615 |
Anne-Claire Godet1, Florian David2, Fransky Hantelys3, Florence Tatin4, Eric Lacazette5, Barbara Garmy-Susini6, Anne-Catherine Prats7.
Abstract
The cellular stress response corresponds to the molecular changes that a cell undergoes in response to various environmental stimuli. It induces drastic changes in the regulation of gene expression at transcriptional and posttranscriptional levels. Actually, translation is strongly affected with a blockade of the classical cap-dependent mechanism, whereas alternative mechanisms are activated to support the translation of specific mRNAs. A major mechanism involved in stress-activated translation is the internal ribosome entry site (IRES)-driven initiation. IRESs, first discovered in viral mRNAs, are present in cellular mRNAs coding for master regulators of cell responses, whose expression must be tightly controlled. IRESs allow the translation of these mRNAs in response to different stresses, including DNA damage, amino-acid starvation, hypoxia or endoplasmic reticulum stress, as well as to physiological stimuli such as cell differentiation or synapse network formation. Most IRESs are regulated by IRES trans-acting factor (ITAFs), exerting their action by at least nine different mechanisms. This review presents the history of viral and cellular IRES discovery as well as an update of the reported ITAFs regulating cellular mRNA translation and of their different mechanisms of action. The impact of ITAFs on the coordinated expression of mRNA families and consequences in cell physiology and diseases are also highlighted.Entities:
Keywords: IRES; ITAF; chaperone; gene regulation; hnRNP; lncRNA; mRNA; nucleocytoplasmic translocation; ribosome; stress; stress granules; therapeutic targets; translation; translation initiation factor
Mesh:
Substances:
Year: 2019 PMID: 30791615 PMCID: PMC6412753 DOI: 10.3390/ijms20040924
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The regulation of the (lymph)angiogenic growth factor expression during hypoxia: (Lymph)angiogenic growth factors are regulated at the transcriptional and/or translational levels during hypoxia. In conditions of tumoral hypoxia, the regulation is both transcriptional and translational through the internal ribosome entry site (IRES)-dependent mechanism, whereas during cardiac ischemia in hypoxic cardiomyocytes, most regulation is translational [72]. The IRESs of (lymph)angiogenic growth factor mRNAs are activated during early hypoxia by an HIF1-independent mechanism.
An update of the reported IRES trans-acting factors (ITAFs) that regulate cellular IRESs. The different reported ITAFs regulating cellular IRESs are indicated. They are dispatched into three classes (see text). For each ITAF, the regulated IRESs, the type of regulation (activator or inhibitor), the described stimuli able to trigger their activity, the roles in cell physiology and diseases as well as the corresponding references are shown.
| ITAF | Also Known As | Regulated IRESs | Regulation | Stimulus | Roles in Cell Physiology and Diseases | References |
|---|---|---|---|---|---|---|
|
| ||||||
| Annexin A2 | p53 | activator | ER stress | cancer | [ | |
| CUGBP1 | CELF1 | SHMT-1, p27kip | inhibitor/activator | UV irradiation | DNA repair, cell proliferation | [ |
| DAP5 | P97, NAT1, eIF4GII | Bcl-2, Bcl-XL, BAX, APAF-1, DAP5, Δ40p53, CDK1, HIAP2, c- | activator | viral infection, apoptosis, ER stress, serum starvation, g-irradiation | cell survival or programmed cell death | [ |
| FBP3 | FUBP3 | TXNIP | activator | Renal cell carcinoma | [ | |
| FUS | LEF1 | activator | Cancer, amyotrophic lateral sclerosis | [ | ||
| GRSF1 | c- | activator | cancer | [ | ||
| H-ferritin | SHMT-1 | activator | UV irradiation | DNA repair | [ | |
| HDMX | p53 | activator | DNA damage | tumour suppression | [ | |
| hnRNPA1 | XIAP, FGF2, Nfil3, SREBP1-a, c- | activator/inhibitor | FGF2, lipid accumulation, ER stress, osmotic shock, UV irradiation | multiple myeloma, circadian oscillation | [ | |
| hnRNPC | hnRNP C1/C2 | p53, IGF1R, unr, c- | activator | DNA damage, transcription inhibition, growth stimulus, cell cycle | inhibition of apoptosis, cancer | [ |
| hnRNPD | JKTBP1 | NRF | activator | UV irradiation | cell survival | [ |
| hnRNPE | PCBP, alphaCP | c- | activator | Chemotoxic stress | cell survival, tumorigenesis | [ |
| hnRNPH2 | SHMT1 | activator | UV irradiation | DNA repair | [ | |
| hnRNPK | c-myc | activator | myoblast differentiation, proliferation, tumor progression | [ | ||
| hnRNPL | Cat-1, p53, LINE-1 | activator | Amino-acid deprivation/ DNA damage | transposition inhibition | [ | |
| hnRNPM | FGF1 | activator | myoblast differentiation | muscle regeneration | [ | |
| hnRNPQ | NSAP1 | p53, rev-erb-a, Period1, AANAT, Bip, FMRP | activator | apoptosis/ heat shock | circadian oscillation/ cell survival/ axonal growth cone collapse/ Fragile X syndroma, autism | [ |
| hnRNPR | AANAT | activator | circadian oscillation | [ | ||
| HuR | ELAV1 | IGF1R, caspase-2, BcL-XL, XIAP, p27kip, Thrombomodulin | activator/inhibitor | amino-acid deprivation, IL-1b, | cytoprotection, inhibition of apoptosis, cell proliferation, breast cancer | [ |
| La auto antigen | XIAP, Bip, RRBP1 | activator/inhibitor | serum starvation, paclitaxel, adriamycin | cell survival, malignancy maintenance, hepatocellular carcinoma | [ | |
| Mdm2 | HDM2 | p53, XIAP | activator | DNA damage, ionizing radiation | resistance to radiation-induced apoptosis | [ |
| NF45 | iIAP1, XIAP, NRF, ELG | activator | ER stress | polyploidy, senescence | [ | |
| nPTB | IR | activator | cell density, insulin | cell proliferation | [ | |
| nucleolin | p53, VEGFD, LINE-1 | activator/inhibitor | heat shock, DNA damage | transposition inhibition | [ | |
| p54nrb | NONO | c- | activator | myoblast differentiation, nucleolar stress, apoptosis | muscle regeneration | [ |
| PDCD4 | P53, INR, IGF1R, BcL-XL, XIAP | activator/inhibitor | oxidative stress, absence of DNA damage, S6K2 inactivation, FGF2 pathway inhibition | apoptosis, tumour suppression | [ | |
| PSF | SFPQ | p53, c- | activator/inhibitor | nucleolar stress, apoptosis, ER stress | cancer | [ |
| PTB | hnRNPI/ PTBP1 | p53, p27kip, PFK1, IR, Cat-1, APAF1, HIF1α, IRF2, rev-erb-a, unr, c- | activator/inhibitor | DNA damage, hypoxia, ER stress, amino-acid deprivation, cell density, insulin | circadian oscillation, cell cycle arrest, apoptosis | [ |
| RHA | NDH II | p53 | activator | DNA damage | tumour suppression | [ |
| SMAR 1 | p53 | activator/inhibitor | glucose deprivation | cancer (tumor suppressor) | [ | |
| YB1 | YBX1 | c- | activator | hypoxia | multiple myeloma, cancer | [ |
|
| ||||||
| 4E-BP1 | VEGFA, HIF1α, INR | activator | hypoxia, low nutrients, low insulin | cancer, Parkinson | [ | |
| APP (AICD) | Δ40p53 | activator | Alzheimer disease | [ | ||
| eeF1A2 | utrophin A | activator | muscle regeneration | [ | ||
| eIF3 | c- | activator | apoptosis, hypoxia | cancer | [ | |
| eIF4A | c- | activator | apoptosis, hypoxia | cancer | [ | |
| eIF4GI | APAF-1, DAP5, Bcl-2, Bip, c- | activator | apoptosis, hypoxia | cancer | [ | |
| eIF5B |
| activator | apoptosis, hypoxia | cancer | [ | |
| eL38 | Rpl38 | Hox | activator | development | [ | |
| eS19 | Rps19 | BAG1, CSDE1, LamB1 | activator | erythroid differentiation, Diamond-Blackfan anemia | [ | |
| eS25 | Rps25 | APAF-1, BAG1, c- | activator | ER stress | multiple myeloma | [ |
| Gemin5 | TXNIP | activator/inhibitor | Serum starvation | Spinal muscular atrophy | [ | |
| Hepsin (also in plasmic membrane) | unr | inhibitor | Cell cycle regulation, Prostate cancer | [ | ||
| PINK1 (also mitochondrial) | HIF1α | activator | hypoxia | Parkinson | [ | |
| Rack1 | IGF1R | activator/inhibitor | Hepatocellular carcinoma | [ | ||
| TCP80 | NF90, DRBP76 | p53 | activator | DNA damage | tumour suppression | [ |
| uL1 | Rpl10A | IGF2, APP, Chmp2A, Bcl-2 | activator | Alzheimer, leukemia, mitochodrial dysfunction | [ | |
| uL24 | Rpl26 | p53 | activator | DNA damage | tumour suppression | [ |
| uL5 | Rpl11 | BAG1, CSDE1, LamB1 | activator | erythroid differentiation, Diamond-Blackfan anemia | [ | |
| VASH1 (also secreted and nuclear) | Vasohibin 1 | FGF1 | activator | hypoxia | ischemic heart disease | [ |
|
| ||||||
| TRMP | p27kip | inhibitor | induced by p53 | inhibition of cell proliferation, tumor suppressor | [ | |
Figure 2The ITAFs use different mechanisms of action to control IRES-dependent translation. The different reported mechanisms of ITAFs to regulate IRES activities are schematized. For each mechanism, an example is shown with the names of the ITAF and of the IRES. The start point of translation is indicated by an arrow if translation initiation is increased or by a blocked arrow if translation initiation is inhibited. Each mechanism is detailed in the text.